Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IMATINIB Cause Malignant neoplasm progression? 1,716 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,716 reports of Malignant neoplasm progression have been filed in association with IMATINIB (Imatinib). This represents 4.0% of all adverse event reports for IMATINIB.

1,716
Reports of Malignant neoplasm progression with IMATINIB
4.0%
of all IMATINIB reports
701
Deaths
227
Hospitalizations

How Dangerous Is Malignant neoplasm progression From IMATINIB?

Of the 1,716 reports, 701 (40.9%) resulted in death, 227 (13.2%) required hospitalization, and 37 (2.2%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IMATINIB. However, 1,716 reports have been filed with the FAERS database.

What Other Side Effects Does IMATINIB Cause?

Death (9,708) Drug ineffective (2,628) Nausea (2,379) Diarrhoea (2,203) Fatigue (1,810) Vomiting (1,599) Malaise (1,361) Drug intolerance (1,354) Drug resistance (1,293) Rash (1,272)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which IMATINIB Alternatives Have Lower Malignant neoplasm progression Risk?

IMATINIB vs IMBRUVICA IMATINIB vs IMDEVIMAB IMATINIB vs IMEGLIMIN IMATINIB vs IMETELSTAT IMATINIB vs IMIDAPRIL

Related Pages

IMATINIB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression IMATINIB Demographics